PDA Inaugural Conference Draws Participation of Seven National Pharmacopoeias 30 April, 2018

Bethesda, Md., April 30, 2018 – The Parenteral Drug Association (PDA) is proud to present its inaugural Pharmacopoeia Conference held at the Renaissance Wien Hotel, May 29-30, Vienna, Austria, which features lectures from representatives of the pharmacopoeias for Europe, the United States, Russia, China, Japan, India, and Ghana. The European Directorate for Quality of Medicines & Healthcare (EDQM) is chairing the conference.

Representatives from these pharmacopoeias will share approaches to international convergence and the future direction of pharmacopoeias with respect to the overall framework of regulations and guidelines. The pharmaceutical industry will provide insights into their best-practices to effectively and efficiently implement international pharmacopoeial requirements.

“PDA’s inaugural Pharmacopoeia Conference is the first of its kind,” said Richard Johnson, President and CEO, PDA. “No other organization has been able to bring together so many different pharmacopoeias under one roof.”

The World Health Organization, the Eurasian Economic Union Pharmacopoeia Committee, the British Medicines and Healthcare Products Regulatory Agency, and the European Federation of Pharmaceutical Industries and Associations (Efpia) are also participating. Industry representatives from Amgen, Biogen, Ely Lilly and Company, Genentech, Merck Sharp & Dohme FCU, Novartis and Novo Nordisk will also speak.

A pharmaceutical product submitted and marketed in different countries or economic regions must comply with the respective pharmacopoeias legally binding in those countries and regions. Typically, however, international pharmacopoeias differ in the requirements for the same product. Compliance, therefore, becomes a major challenge for pharmaceutical companies.

Members of the press are welcome to apply for a press pass.